Edgewise Therapeutics Inc
(NAS:EWTX)
$
43.07
+1.135 (+2.71%)
Market Cap: 4.68 Bil
Enterprise Value: 4.22 Bil
PE Ratio: 0
PB Ratio: 10.35
GF Score: 28/100 Edgewise Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021 / 09:30PM GMT
Release Date Price:
$26.67
(-0.41%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Hey, good afternoon, everyone. Welcome to the 5:30 session on day 2 at the 42nd Annual Global Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh, and I cover U.S. and European biopharma here at the firm. It's a great pleasure of mine to be able to host Edgewise Therapeutics today in a fireside chat. And with me, we've got 3 members of the management team: Kevin Koch, CEO of the company; Alan Russell, Chief Scientific Officer; and Behrad Derakhshan, who is the Chief Business Officer. So with that, I want to welcome the 3 of you, and thanks for joining.
Kevin Koch
Edgewise Therapeutics, Inc. - President, CEO & Director
No, thank you.
Behrad Derakhshan
Edgewise Therapeutics, Inc. - Chief Business Officer
Thanks, Graig.
Kevin Koch
Edgewise Therapeutics, Inc. - President, CEO & Director
It's great to be involved.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot